To be fair, accelerated R&D amortization (immediate full expensing in the year the expense was incurred) is a tax loophole . Essentially, the default tax treatment of expenses is basically to take the expense same as you would treat it under GAAP, but some people (I am one of them BTW) think that we should put a finger on the scales for the case of legitimate R&D. Now though I happen to think accelerating it is a goo…
i don't know enough about tax codes and how business works to comment on the actual policy, but it sure does seem to me that changes that result in immediate and massive new liabilities are unfair.
Congress knows this: the law was passed in 2017 but only took effect for tax year 2022. This very issue was widely discussed at the time.
That was five years to figure out what to do and your CFO (or at the very least your tax accountant) should have been warning you. I mean, if your tax accountant doesn't know the tax law that's a bad thing.